Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Administrative · Pharmacy · Rheumatology, Dermatology, Pharmacy +1 moreLow impact

MA08.174, Secukinumab (Cosentyx®) for Intravenous Use

Effective date
Not stated in the notice
Identified
Jun 19, 2026

Summary

Independence Blue Cross reissued MA08.174 on 05/27/2026 with no substantive changes to secukinumab (Cosentyx) intravenous coverage criteria for psoriatic arthritis, ankylosing spondylitis, and nonradiographic axial spondyloarthritis. This is a routine policy reaffirmation confirming the company's continuing coverage position; billing teams should verify current authorization requirements remain unchanged.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 4 steps
01No immediate action required.
02This is a routine policy reissuance with no changes to coverage criteria, billing codes, or authorization requirements.
03Billing team should confirm that current secukinumab authorization processes and claim submission procedures for J3247 remain aligned with existing PsA, AS, and nrAxSpA medical necessity requirements (TB screening, DMARD failure/contraindication documentation, age 18+, no biologic/JAK inhibitor combinations).
04File updated policy document for compliance records.

Codes mentioned

J3247L40.50L40.51L40.52L40.53L40.59M45.0M45.1M45.2M45.3M45.4M45.5M45.6

Original notice

MA08.174, Secukinumab (Cosentyx®) for Intravenous Use
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.174, Secukinumab (Cosentyx®) for Intravenous UseLowNo effective date · Pharmacy08.02.28, Secukinumab (Cosentyx®) for Intravenous UseLowEffective Aug 26, 2024 · Pharmacy08.02.28, Secukinumab (Cosentyx®) for Intravenous UseLowEffective Aug 26, 2024 · PharmacyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesRheumatologyDermatologyPharmacyInternal MedicineCode J3247Code L40.50Code L40.51Code L40.52Code L40.53Code L40.59Code M45.0Code M45.1Code M45.2Code M45.3Code M45.4Code M45.5Code M45.6

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account